Passive immunisation against respiratory syncytial virus: A cost-effectiveness analysis

Archives of Disease in Childhood

Volumn 95, Issue 7, 2010, Pages 493-498

  Rietveld, Edwin ^a,b   Steyerberg, Ewout W ^b   Polder, Johan J ^b,c   Veeze, Henk J ^d   Vergouwe, Yvonne ^b   Huysman, Marianne W A ^a   De Groot, Ronald ^a   Moll, Henriëtte A ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d IJSSELLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GENDER; HIGH RISK POPULATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; LOW BIRTH WEIGHT; LUNG DYSPLASIA; MALE; NETHERLANDS; NEWBORN; PASSIVE IMMUNIZATION; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; SEASONAL VARIATION; SENSITIVITY ANALYSIS;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH SERVICES RESEARCH; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; IMMUNIZATION, PASSIVE; INFANT; INFANT, NEWBORN; MALE; NETHERLANDS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SEASONS; SENSITIVITY AND SPECIFICITY;

EID: 77953752955     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.155556     Document Type: Article

References (39)

1. Rietveld E, Vergouwe Y, Steyerberg EW, et al. Respiratory syncytial virus hospitalisation in young children: development of a clinical prediction rule. Pediatr Infect Dis J 2006;25:201-7.
2. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
3. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
4. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27.
5. Eppes SC. Questions about palivizumab (Synagis). Pediatrics 1999;103:534-5; discussion 535-6.
6. Lee SL, Robinson JL. Questions about palivizumab (Synagis). Pediatrics 1999;103:535; author reply 535-6.
7. Moler FW, Brown RW, Faix RG, et al. Comments on palivizumab (Synagis). Pediatrics 1999;103:495-7.
8. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics 1999;104:559-60.
9. Suresh G. IMpact-RSV Study Group report. Pediatrics 1999;104:993; author reply 995.
10. Fox JL. IMpact-RSV Study Group report. Pediatrics 1999;104:994-5.
11. Marchetti A, Lau H, Magar R, et al. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999;21:752-66.
12. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000;154:55-61.
13. Clark SJ, Beresford MW, Subhedar NV, et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000;83:313-6.
14. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000;83:122-7.
15. Lofland JH, O'Connor JP, Chatterton ML, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357-69.
16. Schrand LM, Elliott JM, Ross MB, et al. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother 2001;35:1186-93.
17. Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002;38:352-7.
18. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas medicaid's high-risk children. Arch Pediatr Adolesc Med 2002;156:1251-5.
19. Fariña D, Rodríguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21:287-91.
20. Numa A. Outcome of respiratory syncytial virus infection and a cost-benefit analysis of prophylaxis. J Paediatr Child Health 2000;36:422-7.
21. Roeckl-Wiedmann I, Liese JG, Grill E, et al. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-44. (Pubitemid 36437756)
22. Elhassan NO, Sorbero ME, Hall CB, et al. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-6.
23. Mahadevia PJ, Malinoski FJ. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. Arch Pediatr Adolesc Med 2007;161:519-20; author reply 520.
24. Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 2007;25:55-71.
25. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-41. (Pubitemid 36343482)
26. Klassen TP. Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion? Arch Pediatr Adolesc Med 2002;156:1180-1.
27. Statistics Netherlands. Statistics Local Districts: http://statline.cbs. nl/statweb, 2002.
28. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68.
29. Bancalari E, Abdenour GE, Feller R, et al. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 1979;95:819-23.
30. Rietveld E, De Jonge HC, Polder JJ, et al. Anticipated costs of hospitalization for respiratory syncytial virus infection in young children at risk. Pediatr Infect Dis J 2004;23:523-9.
31. Miedema CJ, Kors AW, Tjon A Ten WE, et al. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J 2001;20:160-3.
32. Wu SY, Bonaparte J, Pyati S. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics 2004;114:e554-6.
33. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit 2002;24:444-5.
34. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54.
35. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-9.
36. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151:34-42, 42.e1.
37. Moll HA, Rietveld E, de Groot R, et al. Cost-effectiveness of passive immunisation against RSV including long-term effects. 10th Biennial European Conference of the Society for Medical Decision Making; 11-13 June 2006; Birmingham, United Kindgom.
38. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997;16:1-31.
39. Robbins JM, Tilford JM, Jacobs RF, et al. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med 1998;152:358-66.